| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.22 | - | - |
| Q3'25 | $1.13 | $1.19 | +4.9% |
| Q2'25 | $1.46 | $1.08 | -25.9% |
| Q1'25 | $1.12 | $1.25 | +11.6% |
| Q4'24 | $1.04 | $1.04 | +0.8% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $15.4B | - | - |
| Q3'25 | - | $15.2B | - |
| Q2'25 | - | $14.5B | - |
| Q1'25 | - | $13.6B | - |
| Q4'24 | - | $14.9B | - |
Market Data
AZN is currently trading at $170.09, giving AstraZeneca a market cap of 196.50B and a P/E ratio of 25.2. Today's range spans $167.98–$170.32, with shares opening at $168.35 and moving down $1.98 (1.2%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 62/100.
Over the past year AZN has traded between $10700.00 and $15730.00 - the current price is -98.4% off the 52-week low and -98.9% from the high. 36 analysts cover the stock with a Buy consensus and a mean 12-month target of $213.99 (range $184.00–$240.00), implying upside of +25.8%.
Short sellers have a clear thesis in AZN - large-cap, Healthcare, 196.50B market cap. Score: 27/100 (SELL). Sentiment: bullish (62/100). Price: $170.09 (near 52-week lows). The current P/E ratio stands at 25.2. At this capitalization tier, the borrow is relatively easy, the liquidity absorbs the size, and the technical confirmation provides a clean stop-out level. The 52-week range of $10700.00–$15730.00 establishes the structural target zones - and the SELL signal is the systematic entry trigger.
When a large-cap Healthcare name with 196.50B in capitalization prints a SELL signal (27/100) alongside bullish news sentiment (62/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $170.09 (near 52-week lows in the $10700.00–$15730.00 range), the structural support levels are where that sponsorship question gets answered.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).